Technical Data
B0085-01E
BARD1 (BRCA1 Associated Ring Domain 1)
Description:
BRCA1 Associated RING Domain gene 1 (BARD1) interacts with the N terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N terminal RING motif and the C terminal BRCT domain. The RING motif is a cysteine rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic aa substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer. BARD1 also plays a role in mediating apoptotic stress and p53 dependent apoptosis.

Applications:
Suitable for use in ELISA and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:1000
Immunohistochemistry (Formalin fixed paraffin embedded): 10ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
50ug-20°CBlue IceHumanRabbit
Concentration:
~1mg/ml
Immunogen:
Synthetic peptide corresponding to aa108-124 of human BARD1 (KLH).
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, 0.1% sodium azide.
Specificity:
Recognizes human BARD1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.